

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Hammond, *et al*
SERIAL NUMBER : 10/791,516 EXAMINER: Lucas, Zachariah
FILING DATE : March 1, 2004 ART UNIT: 1648
FOR : Prion-Binding Ligands and Methods of Using Same


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. Copies of references are not provided as they were previously cited or submitted to the USPTO in prior applications, Serial No. 09/543,188, filed April 5, 2000 and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). However, charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 18242-507 CON.

Respectfully submitted,


David E. Johnson, Reg. No. 41,874
Attorney for Applicants
c/o MINTZ, LEVIN

Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: March 8, 2005



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/791,516
	Filing Date	March 1, 2004
	First Named Inventor	Hammond
	Group Art Unit	1648
	Examiner Name	Zachariah Lucas
	Attorney Docket Number	18242-507 CON

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,541,294	07/30/96	Horowitz, Bernard			
	*A2	5,723,579	03/03/98	Buettner, Joseph A.			
	*A3	5,750,344	05/12/98	Doyle, Michael V.			
	*A4	5,750,361	05/12/98	Pruisiner, Stanley B.			
	*A5	5,808,011	09/15/98	Gawryl, Maria S.			
	*A6	5,834,318	11/10/98	Buettner, Joseph A.			
	*A7	6,211,149	04/03/01	Chesebro et al.			
	*A8	6,221,614	04/24/01	Prusiner et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
	*B1	WO 93/11155	Proteus Molecular Design Limited		06/10/93		
	*B2	WO 93/23432	New York University and Instituto Nazionale Neurologico C. Besta		11/25/93		
	*B3	WO 96/39834	Soto-Jara et al.		12-39834		
	*B4	WO 97/43649	Ernst-Ludwig Winnacker		11/20/97		
	*B5	WO 98/35236	Enfer Technology Limited		08/13/98		
	*B6	WO 99/15651	Prionics AG		04/01/99	Abstract only	
	*B7	WO 00/02575	V.I. Technologies, Inc.		01/20/00		
	*B8	WO 01/40265	V.I. Technologies, Inc.		06/07/01		
	*B9	WO 01/23425	Universitat Zurich		04/05/01		

OTHER NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	*C1	Baumbach, <i>et al.</i> , BIOPHARM, May, 24-35 (1992).					
	*C2	Brimacombe <i>et al.</i> <i>Biochem. J.</i> , 342:605-613 (1999).					
	*C3	Buettner, <i>et al.</i> , INT. J. PEPTIDE PROTEIN RES., 47:70-83 (1993).					
	*C4	Hornshaw, <i>et al.</i> , <i>Biochem. Biophys. Res. Commun.</i> 207(2): 621-629 (1995).					

	*C5	Hornshaw et al. <i>Biochem. Biophys. Res. Commun.</i> , 214(3):993-999 (1995).
	*C6	Miura, <i>et al.</i> , <i>BIOCHEMISTRY</i> , 38:11560-11569 (1999).
	*C7	Stöckel, <i>et al.</i> , <i>BIOCHEMISTRY</i> 37(20):7185-71983, (1998).
	*C8	Viles, <i>et al.</i> , <i>PROC. NATL. ACAD. SCI. USA</i> , 96:2042-2047, (1999).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. **09/543,188**, filed **April 5, 2000**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2014251v1